Phase I trial to evaluate the tolerability and pharmacokinetics of single ascending doses of MEM 63908 in healthy adult male volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2008
At a glance
- Drugs Facinicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Memory Pharmaceuticals
- 30 Sep 2008 Top-line results are expected from the full phase I program in quarter 4 2008, as reported in a Memory Pharmaceuticals media release.
- 06 Mar 2008 Status changed from recruiting to completed, according to a Memory Pharmaceuticals media release.
- 13 Sep 2007 New trial record.